Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.

Abstract

BACKGROUND The objective of this study was to evaluate the efficacy and safety of dovitinib in patients with adenoid cystic carcinoma (ACC). METHODS ACC patients with documented disease progression within the past 12 months were eligible. Patients received oral dovitinib (500 mg once daily for 5 consecutive days followed by a 2-day rest every week) until… (More)
DOI: 10.1002/cncr.29401

Topics

5 Figures and Tables